Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 308

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trial

Wassenberg, Siegfried, Rau, Rolf, Steinfeld, Paul, Zeidler, Henning, Low‐Dose Prednisolone Therapy Study Group · 2005 · Arthritis & Rheumatism

Abstract

Objective: To assess the effect of 5 mg/day prednisolone on disease progression in patients with early rheumatoid arthritis (RA) receiving standardized disease‐modifying antirheumatic drug (DMARD) therapy. Methods: Patients with active RA of <2 years' duration were randomly assigned in a double‐blinded manner to receive prednisolone or placebo while starting concomitant DMARD therapy (gold sodium thiomalate or methotrexate). Hand and foot radiographs were taken at baseline and at 6, 12, and 24 months and were evaluated according to the Ratingen score and the total modified Sharp/van der Heijde score (SHS). Results: Of 192 included patients, 166 were available for the intent‐to‐treat analysis (ITT). Seventy‐six patients completed the study per protocol (PP). Radiographic progression (increase in the Ratingen score) was significantly less with prednisolone than with placebo. The difference in the progression rate between the groups was greatest in the first 6 months. At 24 months in the ITT population, the least squares (LS) mean difference was 3.14 (95% confidence interval [95% CI] 0.94, 5.34),P= 0.006. The results were confirmed by the total SHS in the ITT population (LS mean difference 7.20 [95% CI 0.93, 13.47],P= 0.022) and with the PP population. Clinical and functional outcomes tended to be better and the rate of remissions was higher in the prednisolone group. Side effects were observed more frequently in the prednisolone group than in the control group: weight gain (4 versus 0 patients), hypertension (6 versus 2 patients), glaucoma (3 versus 0 patients), Cushing's syndrome (5 versus 0 patients), gastric distress (9 versus 4 patients), and gastric ulcers (only with concomitant nonsteroidal antiinflammatory drug therapy; 3 versus 0 patients). No new lumbar fractures were found in either group. Conclusion: The very low daily dose of 5 mg prednisolone given over 2 years in combination with background DMARD therapy substantially decreased radiographic progression in early RA at low risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.21421

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 308

Metadata

Authors
Wassenberg, S., Rau, R., Steinfeld, P., Zeidler, H., & Low‐Dose Prednisolone Therapy Study Group
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2005-10-27
Volume
52
Issue
11
Pages
3371-3380
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2037939754
Cited by
308
References
35
FWCI
11.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1002/art.21421
The paper
Wassenberg, S., Rau, R., Steinfeld, P., Zeidler, H., & Low‐Dose Prednisolone Therapy Study Group. (2005). Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.21421

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.